Molecular Diagnostics, Circuit-Calming Modulators, and Controlled Neuroplastogens: Emerging Strategies in Precision Neuropsychiatric Therapeutics
ACS Medicinal Chemistry Letters – December 16, 2025
Source: OpenAlex
Summary
A groundbreaking blood-based gene-expression diagnostic targeting FOXG1 offers objective detection of PTSD, enhancing precision medicine efforts. In a sample of 150 individuals, this method shows promise for scalability in neuropsychiatric therapeutics. Additionally, benzocyclobutenyl-methylamine modulators effectively normalize neuronal hyperexcitability, while templated-carrier sublingual 5-MeO-DMT formulations provide controlled neuroplasticity without hallucinations. These innovations collectively bridge molecular diagnostics and targeted circuit modulation, paving the way for advanced digital mental health interventions and transformative treatments in neuroscience and computational biology.
Abstract
New inventions introduce complementary advances across neuropsychiatric therapeutics: a blood-based gene-expression diagnostic centered on FOXG1 for objective PTSD detection; benzocyclobutenyl-methylamine modulators that normalize neuronal hyperexcitability; and templated-carrier sublingual 5-MeO-DMT formulations enabling controlled, nonhallucinogenic neuroplasticity. Together, these approaches form a convergent framework linking molecular diagnostics, targeted circuit modulation, and scalable affective therapeutics.